홈MPSYF • OTCMKTS
add
모포시스
시장 뉴스
재무
손익계산서
수익
순이익
| (EUR) | 2024년 6월info | 전년대비 변동 |
|---|---|---|
수익 | 3464.38만 | -34.84% |
운영비 | 7893.35만 | -17.78% |
순이익 | -7919.31만 | -7.07% |
순이익률 | -228.59 | -64.30% |
주당 수익 | — | — |
EBITDA | -4437.82만 | 6.70% |
유효 세율 | — | — |
대차대조표
총자산
총부채
| (EUR) | 2024년 6월info | 전년대비 변동 |
|---|---|---|
현금 및 단기 투자 | 5.12억 | -23.74% |
총자산 | 17.05억 | -20.42% |
총부채 | 20.40억 | -3.37% |
총자기자본 | -3.35억 | — |
발행 주식 | 3766.27만 | — |
주가순자산비율 | -8.24 | — |
총자산이익률 | -6.44% | — |
자본이익률 | -7.90% | — |
현금 흐름
순현금흐름
| (EUR) | 2024년 6월info | 전년대비 변동 |
|---|---|---|
순이익 | -7919.31만 | -7.07% |
영업 현금 흐름 | -1.31억 | -4.25% |
투자 현금 흐름 | 1.17억 | 402.25% |
자금 조달 현금 흐름 | -298.13만 | 36.22% |
순현금흐름 | 241.34만 | 102.25% |
잉여 현금 흐름 | 3.95억 | 464.18% |
정보
MorphoSys AG is a German biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany, and has a wholly owned subsidiary, MorphoSys US Inc., in Boston, Massachusetts, in the US. The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are being investigated for a variety of diseases. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also has a proprietary pipeline with a focus on cancer and autoimmune diseases.
MorphoSys AG was listed on the Frankfurt Stock Exchange and on the US Nasdaq stock exchange. Novartis agreed to acquire the company in February 2024. Wikipedia
CEO
설립
1992
웹사이트
직원 수
446
